个人简历

B.S. Peking University (2002)\r
Ph.D. University of Pittsburgh (2007)\r
Postdoc, MIT (2011)\r
\r
Dr. Guangyu Zhu obtained his B.Sc. in Chemistry from Peking University (2002), where he developed a strong passion for biological chemistry and drug discovery. He moved to the United States and obtained a Ph.D. in Biological Chemistry from the Department of Chemistry at the University of Pittsburgh (2007), where he worked on anticancer drug development and discovery. He subsequently did his postdoc at the Massachusetts Institute of Technology (MIT), working on the mechanism of action of cisplatin, one of the most widely used chemotherapeutic drugs in the clinic. He joined the City University of Hong Kong as an Assistant Professor in 2011. Dr. Zhu's research interest lies at the interface of chemistry and biology, focusing on anticancer drug development and mechanism. His current research projects include the synthesis and biological evaluation of novel metal-based anticancer agents, the development of cancer-specific nanomedicine to conquer cisplatin resistance, and the screening of biologically active small-molecule anticancer agents and their target validation, by using interdisciplinary approaches and methods in the areas of biological chemistry, medicinal chemistry, molecular biology, and chemical biology.

研究领域

"""""Research Overview\r
The research in the Zhu Group lies at the interface of chemistry and biology in the study of the mechanisms of anticancer drugs

近期论文

Yan, Q., Duan, M., Chen, C., Deng, Z., Wu, M., Yu, P., He, M.*, Zhu, G.*, Houk, K. N.*, and Sun, J.* (2022) Organocatalytic discrimination of non-directing aryl and heteroaryl groups: enantioselective synthesis of bioactive indole-containing triarylmethanes. Chem. Sci. 13, 5767–5773\r
\r
Yao, H., Wang, Z.*, Wang, N., Deng, Z., Liu, G., Zhou, J., Chen, S., Shi, J., and Zhu, G.* (2022) Enhancing circulation and tumor accumulation of carboplatin via an erythrocyte-anchored prodrug strategy. Angew. Chem. Int. Ed. 61, e202203838\r
\r
Ma, L., Li, L., and Zhu, G.* (2022) Platinum-containing heterometallic complexes in cancer therapy: advances and perspectives. Inorg. Chem. Front. 9, 2424–2453\r
\r
Yao, H., and Zhu, G.* (2022) A platinum-based fluorescent “turn on” sensor to decipher the reduction of platinum(IV) prodrugs. Dalton Trans. 51, 5394–5398\r
\r
Chen, S., Ng, K. Y., Zhou, Q., Yao, H., Deng, Z., Tse, M.-K., and Zhu, G.* (2022) The influence of different carbonate ligands on the hydrolytic stability and reduction of platinum(IV) prodrugs. Dalton Trans. 51, 885–897\r
\r
Li, B., Liu, J., Lyu, F., Deng, Z., Yi, B., Du, P., Yao, X., Zhu, G., Xu, Z., Lu, J., and Li, Y. Y. (2022) Mineral hydrogel from inorganic salts: biocompatible synthesis, all-in-one charge storage, and possible implications in the origin of life. Adv. Funct. Mater. 32, 2109302\r
\r
Xue, Y., Feng, X., Fan, X., Zhu, G., McLaughlan, J., Chen, X., and Zhang, W. (2022) Exosomes for early diagnosis of cancers. Small Struct. 3, 2100096\r
\r
Wang, N., Deng, Z., Zhu, Q., Zhao, J., Xie, K., Shi, P., Wang, Z., Chen, X., Wang, F., Shi, J., and Zhu, G.* (2021) An erythrocyte-delivered and near-infrared photoactivatable oxaliplatin nanoprodrug for enhanced antitumor efficacy and immune response. Chem. Sci. 12, 14353-14362\r
\r
Yao, H., Gunawan, Y. F., Liu, G., Tse, M.-K., and Zhu, G.* (2021) Optimization of axial ligands to promote the photoactivation of BODIPY-conjugated platinum(IV) anticancer prodrugs. Dalton Trans. 50, 13737–13747\r
\r
Zhou, B., Ou, W., Zhao,C., Shen, J., Zhang, G., Tang, X., Deng, Z., Zhu, G., Li, Y. Y., Lu, J. (2021) Insertable and reusable SERS sensors for rapid on-site quality control of fish and meat products. Chem. Eng. J. 426, 130733\r
\r
Qi, S., Zhang, Y., Liu, G., Chen, J., Li, X., Yang, Y., Shi, J., Lee, C.-S., Lai, P.*, Zhu, G.*, Wang, L.*, and Fang, C.* (2021) Plasmonic-doped melanin-mimic for CXCR4-targeted NIR-II photoacoustic computed tomography-guided photothermal ablation of orthotopic hepatocellular carcinoma. Acta Biomater. 129, 245-257\r
\r
Xu, Z., Tang, W. K., Zhou, Q., Chen, S., Siu, C.-K.*, and Zhu, G.* (2021) On the hydrolytic stability of unsymmetric platinum(IV) anticancer prodrugs containing axial halogens. Inorg. Chem. Front. 8, 3794-3802\r
\r
Xu, Z., Deng, Z., Wang, Z., and Zhu, G.* (2021) Recent advances in the synthesis, stability, and activation of Pt(IV) prodrugs. Coord. Chem. Rev. 442, 213991\r
\r
Deng, Z., Li, C., Chen, S., Zhou, Q., Xu, Z., Wang, Z., Yao, H., Hirao, H., and Zhu, G.* (2021) An intramolecular photoswitch can significantly promotes photoactivation of Pt(IV) prodrugs. Chem. Sci. 12, 6536-6542 \r
\r
Ren, B., Chen, B., Zhao, J., Guo, Y., Zhang X., Chen, X., Du, Y., Deng, Z., Zhu, G., and Wang, F. (2021) Synthesis of core–shell ScF3 nanoparticles for thermal enhancement of upconversion. Chem. Mater. 33, 158-163\r
\r
Deng, Z., Wang, N., Ai, F., Wang, Z.*, and Zhu, G.* (2021) Nanomaterial-mediated platinum drug-based combinatorial cancer therapy. VIEW 2, 20200030 \r
\r
Li, X.†, Duan, M.†, Deng, Z.†, Shao, Q., Chen, M., Zhu, G.*, Houk, K.N.*, and Sun, J.* (2020) Catalytic enantioselective synthesis of chiral tetraarylmethanes. Nat. Catal. 3, 1010-1019\r
\r
Yao, H., Chen, S., Deng, Z., Tse, M.-K., Matsuda, Y., and Zhu, G.* (2020) BODI-Pt, a green-light activatable and carboplatin-based platinum(IV) anticancer prodrug with enhanced activation and cytotoxicity. Inorg. Chem. 59, 11823–11833\r
\r
Chen, S., Yao, H., Zhou, Q., Tse, M.-K., Gunawan, Y. F., and Zhu, G.* (2020) Stability, reduction, and cytotoxicity of platinum(IV)-based anticancer prodrugs bearing carbamate axial ligands: Comparison with their carboxylate analogues. Inorg. Chem. 59, 11676–11687\r
\r
Deng, Z., Wang, N., Liu, Y., Xu, Z., Wang, Z., Lau, T.-C., and Zhu, G.* (2020) A photocaged, water-oxidizing, and nucleolus-targeted Pt(IV) complex with a distinct anticancer mechanism. J. Am. Chem. Soc. 142, 7803-7812